DNA damage response (DDR) is critically important for cell survival, genome maintenance, and its defect has been exploited therapeutically in cancer treatment. Many DDR-targeting agents have been generated and have entered the clinic and/or clinical trials. In order to provide a global and unbiased view of DDR network, we designed a focused CRISPR library targeting 365 DDR genes and performed CRISPR screens on the responses to several DDR inhibitors and DNA-damaging agents in 293A cells. With these screens, we determined responsive pathways enriched under treatment with different types of small-molecule agents. Additionally, we showed that POLE3/4-deficient cells displayed enhanced sensitivity to an ATR inhibitor, a PARP inhibitor, and camptothecin. Moreover, by performing DDR screens in isogenic TP53 wild-type and TP53 knock-out cell lines, our results suggest that the performance of our CRISPR DDR dropout screens is independent of TP53 status. Collectively, our findings indicate that CRISPR DDR screens can be used to identify potential targets of small-molecule drugs and reveal that TP53 status does not affect the outcome of these screens.
Keywords: CRISPR screen; DNA damage response; TP53.
Published by Elsevier B.V.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no conflicts of interest.
Parallel CRISPR-Cas9 screens clarify impacts of p53 on screen performance.Elife. 2020 May 22;9:e55325. doi: 10.7554/eLife.55325. Elife. 2020. PMID: 32441252
Genome-wide Screens Implicate Loss of Cullin Ring Ligase 3 in Persistent Proliferation and Genome Instability in TP53-Deficient Cells.Cell Rep. 2020 Apr 7;31(1):107465. doi: 10.1016/j.celrep.2020.03.029. Cell Rep. 2020. PMID: 32268084 Free PMC article.
Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.Curr Med Chem. 2017;24(15):1586-1606. doi: 10.2174/0929867323666161214114948. Curr Med Chem. 2017. PMID: 27978798 Free PMC article. Review.
Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.J Exp Clin Cancer Res. 2016 Nov 24;35(1):179. doi: 10.1186/s13046-016-0456-2. J Exp Clin Cancer Res. 2016. PMID: 27884198 Free PMC article. Review.
CRISPR Screens Provide a Comprehensive Assessment of Cancer Vulnerabilities but Generate False-Positive Hits for Highly Amplified Genomic Regions.Cancer Discov. 2016 Aug;6(8):900-13. doi: 10.1158/2159-8290.CD-16-0178. Epub 2016 Jun 3. Cancer Discov. 2016. PMID: 27260157